UniProtKB/Swiss-Prot P21359: Variant p.Asp176Glu

Neurofibromin
Gene: NF1
Feedback?

Variant information Variant position:

176 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Aspartate (D) to Glutamate (E) at position 176 (D176E, p.Asp176Glu). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Similar physico-chemical property. Both residues are medium size and acidic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description:

Found in mismatch repair deficient cancer cells; also found in a cutaneous neurofibroma from a patient with neurofibromatosis; somatic mutation. Any additional useful information about the variant.
Other resources:

Links to websites of interest for the variant.

Variant rs112306990 [ dbSNP | Ensembl ]

Sequence information Variant position:

176 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

2839 The length of the canonical sequence.
Location on the sequence:

RISTRLQELTVCSEDNVDVH D IELLQYINVDCAKLKRLLKE The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         RISTRLQELTVCSEDNVDVHDIELLQYINVDCAKLKRLLKE

Mouse                         RISTRLQELTVCSEDNVDVHDIELLQYINVDCAKLKRLLKE

Rat                           RISTRLQELTVCSEDNVDVHDIELLQYINVDCAKLKRLLKE

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	2 – 2839	Neurofibromin
Chain	2 – 1305	Neurofibromin truncated
Helix	174 – 181

Literature citations
Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain.
Fahsold R.; Hoffmeyer S.; Mischung C.; Gille C.; Ehlers C.; Kuecuekceylan N.; Abdel-Nour M.; Gewies A.; Peters H.; Kaufmann D.; Buske A.; Tinschert S.; Nuernberg P.;
Am. J. Hum. Genet. 66:790-818(2000)
Cited for: VARIANTS NF1 PRO-216; PRO-357; CYS-491; PRO-549; THR-581; ARG-583; PHE-665; PRO-695; PRO-763; SER-777; LYS-780; PRO-781; PRO-847; SER-1156; PRO-1250; GLN-1276; PRO-1276; PRO-1446; VAL-1605 AND ILE-2507; VARIANT GLU-176; Neurofibromatosis type 1 gene as a mutational target in a mismatch repair-deficient cell type.
Wang Q.; Montmain G.; Ruano E.; Upadhyaya M.; Dudley S.; Liskay R.M.; Thibodeau S.N.; Puisieux A.;
Hum. Genet. 112:117-123(2003)
Cited for: VARIANTS NF1 TYR-93; VAL-604; ARG-844 AND PRO-898; VARIANTS ASP-74; GLU-176; ARG-712 AND GLN-1276; Novel and recurrent mutations in the NF1 gene in Italian patients with neurofibromatosis type 1.
De Luca A.; Schirinzi A.; Buccino A.; Bottillo I.; Sinibaldi L.; Torrente I.; Ciavarella A.; Dottorini T.; Porciello R.; Giustini S.; Calvieri S.; Dallapiccola B.;
Hum. Mutat. 23:629-629(2004)
Cited for: VARIANTS NF1 ASN-157; ARG-629; SER-777; LYS-780; ARG-784; PRO-847; GLU-848; ARG-968; ASN-1444; LEU-1953 DEL AND ARG-2001; VARIANT GLU-176; Automated comparative sequence analysis identifies mutations in 89% of NF1 patients and confirms a mutation cluster in exons 11-17 distinct from the GAP related domain.
Mattocks C.; Baralle D.; Tarpey P.; ffrench-Constant C.; Bobrow M.; Whittaker J.;
J. Med. Genet. 41:E48-E48(2004)
Cited for: VARIANTS NF1 ARG-31; PRO-145; ARG-324; VAL-337; CYS-489; PRO-532; ARG-574; ARG-629; PHE-665; PHE-844; PRO-844; MET-991 DEL; VAL-1073; ARG-1196; GLY-1276; GLN-1276; GLU-1430; GLU-1459 DEL AND GLY-1489; VARIANTS GLU-176 AND CYS-873; Exploring the somatic NF1 mutational spectrum associated with NF1 cutaneous neurofibromas.
Thomas L.; Spurlock G.; Eudall C.; Thomas N.S.; Mort M.; Hamby S.E.; Chuzhanova N.; Brems H.; Legius E.; Cooper D.N.; Upadhyaya M.;
Eur. J. Hum. Genet. 20:411-419(2012)
Cited for: VARIANTS GLU-176; THR-330; ASP-393; LEU-393; PRO-519; THR-776 AND PHE-1484;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.